Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera (NASDAQ: NTRA) reported two peer‑reviewed studies showing clinical utility of Signatera, its personalized ctDNA assay, in anal squamous cell carcinoma (ASCC) and locally advanced rectal cancer (LARC).
In ASCC (n=84), Signatera‑negative or cleared patients had 100% one‑year OS and PFS, while post‑CRT ctDNA‑positive patients showed worse one‑year outcomes (63% OS; 44% PFS). In LARC (n=220), Signatera positivity after neoadjuvant therapy predicted higher regrowth risk (HR 4.62; p=0.003) and much higher relapse (88.0% vs 11.5%; p<0.0001).
Natera (NASDAQ: NTRA) announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay for rare disease diagnosis, on March 12, 2026.
Zenith uses a whole-genome backbone plus long-read sequencing confirmation to improve detection of hard-to-detect features like tandem repeat expansions. The launch follows an exclusive partnership with MyOme and leverages Natera's EMR integration, clinical support, and nationwide commercial footprint. The company cites 30 million Americans affected by rare disease, typical diagnostic journeys of 4–7 years, and a 2019 U.S. economic burden estimate of $997 billion to frame market need. Natera is presenting Zenith at the 2026 ACMG meeting to showcase platform performance and real-world utilization.
MyOme and Natera (NASDAQ: NTRA) launched the Zenith™ portfolio, a premium exome and genome testing solution integrating MyOme's long-read methylation analysis with Natera's clinical network.
Methylation analysis will be automatically added to all eligible rare disease exome and genome orders starting early Q2 2026, initially as targeted confirmation for select conditions.
Natera (NASDAQ: NTRA) will present 11 abstracts at ASCO GU (Feb 26-28, 2026) showing Signatera MRD's potential across genitourinary cancers.
Key findings include 73–77% ctDNA clearance in MIBC, Signatera-negativity linked to high two-year bladder-intact EFS (88.6% and 91%), and complementary utDNA+ctDNA perioperative stratification.
Natera (NASDAQ: NTRA) reported strong fourth-quarter and full-year 2025 results with significant revenue, margin, volume, and cash improvements.
Total revenue was $665.5M in Q4 2025 (+39.8% YoY) and $2,306.1M for FY2025 (+35.9%). Gross margin improved to 66.9% in Q4 and 64.7% for FY2025. Tests processed rose ~15.0% for the year, and the company achieved a positive cash inflow of $107.6M for FY2025.
Natera (NASDAQ: NTRA) reported Phase 2 SINERGY results in recurrent/metastatic head and neck squamous cell carcinoma showing a 63% objective response rate (17/27) and ctDNA-guided de-escalation in 74% of patients (20/27). Median chemotherapy exposure fell to 2 cycles versus a 6-cycle standard, with grade ≥3 toxicity at 48.1%. Data were presented as an oral plenary at the 2026 MHNCS.
Natera (NASDAQ: NTRA) will release its fourth quarter and full year 2025 results after market close on February 26, 2026. A conference call and webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET.
Investors can join via dial-in (Conference ID 7684785) or the webcast link; a replay will be available at the company investor site.
Natera (NASDAQ: NTRA) launched EDEN, a large U.S. prospective study to evaluate a non-invasive prenatal screening test for early risk assessment of preeclampsia and other adverse pregnancy outcomes. The study plans to enroll up to 7,500 participants at 9–15 weeks' gestation and combines cfDNA, additional analytes, and clinical data.
EDEN builds on prior research linking cfDNA markers to pregnancy complications and aims to detect earlier-onset and more severe preeclampsia with routine prenatal data.
Natera (NASDAQ: NTRA) submitted a premarket approval (PMA) to the U.S. FDA for Signatera CDx to detect molecular residual disease (MRD) in muscle-invasive bladder cancer (MIBC) patients who may benefit from atezolizumab.
The PMA is supported by randomized, double-blind phase 3 IMvigor011 data showing Signatera-guided therapy improved disease-free and overall survival for Signatera-positive patients, while Signatera-negative patients had low recurrence risk without adjuvant immunotherapy. Results were presented at ESMO and published in The New England Journal of Medicine.
Natera (NASDAQ: NTRA) completed enrollment in ACES-EMB, the first randomized-controlled trial comparing donor-derived cell-free DNA (dd-cfDNA) surveillance with routine endomyocardial biopsy (EMB) for heart transplant rejection monitoring.
The trial enrolled >300 patients across 17 U.S. transplant centers; participants randomized at one month post-transplant will be followed for 12 months.